药明康德及药明生物再澄清，称不会对美国构成国家安全风险

香港0102-14

药明系再次发出澄清公告。药明康德（2359）重申没有人类基因组学业务，现有各类业务不会收集人类基因组数据。同时指出提供基于合同的研究、开发和生产服务，通过赋能全球制药和生命科学行业，致力于推动新药研发并为患者带来挽救生命的新药。公司亦指出注意到，有美国议员于2024年2月12日致函美国商务部、财政部和国防部，其内容有关本公司。公司表示一向欢迎监管机构对行业监管，过去亦多次成功通过美国政府的审查。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

wenson6511
02-14
wenson6511
说说你对这篇新闻的看法...

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2411317328?lang=zh_CN&edition=full","thumbnail":"https://cdn.hk01.com/di/media/images/dw/20220310/578513246076538880087962.png/-bOyz0eXCE3Kd8ClV-mm1zJ2zupVfwS3jyFVr48hVa8","is_english":false,"pubTime":"2024-02-14 08:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2411317328","market":"hk","top_or_hot":-1,"title":"药明康德及药明生物再澄清，称不会对美国构成国家安全风险","media":"香港01","content":"<div>\n<p>药明系再次发出澄清公告。药明康德（2359）重申没有人类基因组学业务，现有各类业务不会收集人类基因组数据。同时指出提供基于合同的研究、开发和生产服务，通过赋能全球制药和生命科学行业，致力于推动新药研发并为患者带来挽救生命的新药。公司亦指出注意到，有美国议员于2024年2月12日致函美国商务部、财政部和国防部，其内容有关本公司。公司表示一向欢迎监管机构对行业监管，过去亦多次成功通过美国政府的审查。...</p>\n\n<a href=\"https://www.hk01.com/%E8%B2%A1%E7%B6%93%E5%BF%AB%E8%A8%8A/990624/%E8%97%A5%E6%98%8E%E5%BA%B7%E5%BE%B7%E5%8F%8A%E8%97%A5%E6%98%8E%E7%94%9F%E7%89%A9%E5%86%8D%E6%BE%84%E6%B8%85-%E7%A8%B1%E4%B8%8D%E6%9C%83%E5%B0%8D%E7%BE%8E%E5%9C%8B%E6%A7%8B%E6%88%90%E5%9C%8B%E5%AE%B6%E5%AE%89%E5%85%A8%E9%A2%A8%E9%9A%AA\">网页链接</a>\n\n</div>\n","source":"hk01_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药明康德及药明生物再澄清，称不会对美国构成国家安全风险</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药明康德及药明生物再澄清，称不会对美国构成国家安全风险\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-14 08:37 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.hk01.com/%E8%B2%A1%E7%B6%93%E5%BF%AB%E8%A8%8A/990624/%E8%97%A5%E6%98%8E%E5%BA%B7%E5%BE%B7%E5%8F%8A%E8%97%A5%E6%98%8E%E7%94%9F%E7%89%A9%E5%86%8D%E6%BE%84%E6%B8%85-%E7%A8%B1%E4%B8%8D%E6%9C%83%E5%B0%8D%E7%BE%8E%E5%9C%8B%E6%A7%8B%E6%88%90%E5%9C%8B%E5%AE%B6%E5%AE%89%E5%85%A8%E9%A2%A8%E9%9A%AA><strong>香港01</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>药明系再次发出澄清公告。药明康德（2359）重申没有人类基因组学业务，现有各类业务不会收集人类基因组数据。同时指出提供基于合同的研究、开发和生产服务，通过赋能全球制药和生命科学行业，致力于推动新药研发并为患者带来挽救生命的新药。公司亦指出注意到，有美国议员于2024年2月12日致函美国商务部、财政部和国防部，其内容有关本公司。公司表示一向欢迎监管机构对行业监管，过去亦多次成功通过美国政府的审查。...</p>\n\n<a href=\"https://www.hk01.com/%E8%B2%A1%E7%B6%93%E5%BF%AB%E8%A8%8A/990624/%E8%97%A5%E6%98%8E%E5%BA%B7%E5%BE%B7%E5%8F%8A%E8%97%A5%E6%98%8E%E7%94%9F%E7%89%A9%E5%86%8D%E6%BE%84%E6%B8%85-%E7%A8%B1%E4%B8%8D%E6%9C%83%E5%B0%8D%E7%BE%8E%E5%9C%8B%E6%A7%8B%E6%88%90%E5%9C%8B%E5%AE%B6%E5%AE%89%E5%85%A8%E9%A2%A8%E9%9A%AA\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"https://www.hk01.com/%E8%B2%A1%E7%B6%93%E5%BF%AB%E8%A8%8A/990624/%E8%97%A5%E6%98%8E%E5%BA%B7%E5%BE%B7%E5%8F%8A%E8%97%A5%E6%98%8E%E7%94%9F%E7%89%A9%E5%86%8D%E6%BE%84%E6%B8%85-%E7%A8%B1%E4%B8%8D%E6%9C%83%E5%B0%8D%E7%BE%8E%E5%9C%8B%E6%A7%8B%E6%88%90%E5%9C%8B%E5%AE%B6%E5%AE%89%E5%85%A8%E9%A2%A8%E9%9A%AA","article_id":"2411317328","we_media_id":null,"thumbnails":["https://cdn.hk01.com/di/media/images/dw/20220310/578513246076538880087962.png/-bOyz0eXCE3Kd8ClV-mm1zJ2zupVfwS3jyFVr48hVa8"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2411317328","pubTimestamp":1707871056,"columns":[],"sourceInfo":{"source_id":"hk01_highlight","name":"香港01"},"weMediaInfo":null,"summary":"药明系再次发出澄清公告。药明康德（2359）重申没有人类基因组学业务，现有各类业务不会收集人类基因组数据。同时指出提供基于合同的研究、开发和","collect":0,"end_time":0,"defaultTopTitle":"hk01.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603259":"药明康德","02269":"药明生物","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","BK1583":"高瓴概念","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU1720050803.USD":"安联全方位中国股票基金","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0823426308.USD":"法巴中国股票基金","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BK0216":"研究试验","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","BK1610":"ETF&股票定投概念","BK1521":"挪威政府全球养老基金持仓","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0823426480.USD":"法巴中国股票经典Dis","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","BK1576":"医药外包概念","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU1046422090.SGD":"Fidelity Pacific A-SGD","02359":"药明康德","LU0140636845.USD":"施罗德大中华区股票A Acc","BK1589":"北水核心资产"},"translate_title":"PharmaTech and PharmaTech Bio clarified that they would not pose a national security risk to the United States","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"02359":1,"02269":1},"content_text":"药明系再次发出澄清公告。药明康德（2359）重申没有人类基因组学业务，现有各类业务不会收集人类基因组数据。同时指出提供基于合同的研究、开发和生产服务，通过赋能全球制药和生命科学行业，致力于推动新药研发并为患者带来挽救生命的新药。公司亦指出注意到，有美国议员于2024年2月12日致函美国商务部、财政部和国防部，其内容有关本公司。公司表示一向欢迎监管机构对行业监管，过去亦多次成功通过美国政府的审查。但是强烈反对针对公司的误导性指称、不确实认定和未经正当程序的预判行动。公司坚信在过去没有、现在和未来都不会对美国构成国家安全风险，即便美国政府再次对公司进行审查亦将得出相同结论。事实上，药明康德是全球制药和生命科学行业的重要贡献者之一。药明生物强调自己属独立公司至于同系的药明生物（2269）亦发出公告，指出注意到有美国”议员于2月12日致函美国部分政府部门，其中提到公司。公司澄清并非药明康德新药，信函中的相关陈述失实，又强调公司是一家在香港联合交易所有限公司主板上市的独立公众公司，并独立运营其业务。药明生物指出完全支持监管机构对行业监管，但强烈反对任何在未经正当考虑事实的情况下针该公司的不正确的陈述和缺乏根据的指控。公司谨此重申其过去没有、现在或未来也不会对美国或其他国家的国家安全构成风险，始终并将一贯遵守合规经营的原则，并遵照开展业务地区适用的法律法规运营。公司将一如既往地致力为全球医疗健康服务并作出贡献。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":273778850001024,"gmtCreate":1707878355143,"gmtModify":1707878550534,"author":{"id":"4098062154319340","authorId":"4098062154319340","name":"wenson6511","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4098062154319340","authorIdStr":"4098062154319340"},"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/273778850001024","repostId":2411317328,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2411317328"}